ZYN002 Recent News
Zynerba's Clinical-Trial Miss Devastates Stock Price
Canton Fitzgerald Reiterates Overweight Rating, $28 Price Target On Zynerba
What Analysts Expect For Zynerba's Upcoming Wave Of Data
Catalysts Growing Like Weeds For Zynerba Next Quarter
It's High Time For Zynerba Positives: Investors Await 3 Key Mid-Stage Trial Reads On Cannabidiol ZYN002
Zynerba Could See 3 Clinical Study Catalysts In 2017's First Half
Zynerba CEO Talks Election, Balance Sheet And Huge Osteoarthritis Market Potential
A Higher Probability For Success Is Not Baked Into Zynerba's Valuation
GW Pharma's Epidiloex Data Is Good News For Zynerba